1-Methylbutylpyrazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-Methylbutylpyrazine
• 英文别名: 2-pentan-2-ylpyrazine
• 化学式: C₉H₁₄N₂
• 分子量: 150.22
• InChiKey: MRGPJALDSXTAJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH<br/>[FR] INHIBITEURS DE L'ACTIVITÉ DÉSHYDROGÉNASE À CHAÎNE COURTE POUR FAVORISER LA NEUROGENÈSE ET INHIBER LA MORT DES CELLULES NERVEUSES
  申请人：UNIV CASE WESTERN RESERVE

  公开号：WO2018017582A1

  公开（公告）日：2018-01-25

  A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and/or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and/or treating a disease, disorder, and/or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

  在需要的受试者中，促进神经保护的方法包括向受试者施用治疗有效量的15-PGDH抑制剂，以防止轴突退化、神经细胞死亡和/或胶质细胞损伤，增强学习和记忆的神经信号传导，刺激受伤后的神经再生，以及/或治疗神经系统的疾病、紊乱和/或状况。
• METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：Yumanity Therapeutics

  公开号：US20180193325A1

  公开（公告）日：2018-07-12

  The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

  本公开提供了在治疗神经系统疾病方面有用的化合物和方法。本发明的化合物可以单独或与其他药用活性剂结合使用，用于治疗或预防神经系统疾病。
• Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10696713B2

  公开（公告）日：2020-06-30

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了式 I 的化合物、 包含这些化合物的药物组合物，以及使用这些化合物预防或治疗 FXR 介导或 TGR5 介导的疾病或病症的方法。
• Methods for the treatment of neurological disorders
  申请人：Yumanity Therapeutics, Inc.

  公开号：US10973810B2

  公开（公告）日：2021-04-13

  The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

  本公开提供了用于治疗神经系统疾病的化合物和方法。本发明的化合物可单独使用或与其他药物活性剂结合使用，用于治疗或预防神经系统疾病。
• BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190194245A1

  公开（公告）日：2019-06-27

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.